Tag: Pulmonary Embolism

REBEL Cast Ep125: 1st 48 Hours of PE Management – How Good Is Unfractionated Heparin?

Background: The mainstay of treatment for symptomatic pulmonary embolism  (PE) is anticoagulation (AC).  Patients with higher-risk PE may require advanced interventions such as thrombolytic therapy, surgical thrombectomy, or even extracorporeal membrane oxygenation (ECMO). Because of its short half-life and availability …

Read More
CardiovascularHematology and OncologyResuscitationThoracic and Respiratory

REBEL Cast Ep123: Reduced-Dose Systemic Peripheral Alteplase in Massive PE?

Background: Massive pulmonary embolism  defined as sustained hypotension (SBP <90mmHg)  has a high mortality which is why early recognition and thrombolytic therapy is typically recommended (AHA Class IIA; ESC Class IB) [1]. However, full-dose thrombolytic therapy (Alteplase 100mg (IV) is  associated …

Read More
CardiovascularResuscitationThoracic and Respiratory

Rosh Review MyEMCert Question

Read More
Hematology and OncologyThoracic and Respiratory

VTE Recurrence in Subsegmental PE: What’s the Risk?

Background: The overall mortality and case-fatality rate for pulmonary embolism (PE) are decreasing. Yet reporting is increasing, suggesting we are overdiagnosing PE. Furthermore, management with anticoagulation is not entirely benign and places a potential risk of bleeding upon the patient. …

Read More
Thoracic and Respiratory

The INSPIRATION Trial: Intermediate Dose Anticoagulation in Critically Ill Patients with COVID-19

Background: COVID-19 infection increases the risk of thrombosis due to multiple factors.(Rico-Mesa, 2020). Over the last 2 years, researchers have published 12 RCTs investigating various anticoagulation strategies among patients diagnosed with COVID-19 in multiple clinical settings. To date, only a multiplatform …

Read More
CardiovascularHematology and OncologyInfectious DiseaseThoracic and Respiratory